Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners HSA Plus Formulary Coverage & PA | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealthPartnersPolicy N/A

    HealthPartners HSA Plus 2026 Formulary (drug list and benefit rules)

    Customize your policy alerts

    Sign up for all HealthPartners policy alerts

    Know when HealthPartners releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the 2026 HealthPartners HSA Plus formulary describing covered medicines, tiers, specialty drug rules, and common program edits (prior authorization, step therapy, quantity/age limits) for members and providers.

    Policy Summary
    PayerHealthPartners
    PolicyHealthPartners HSA Plus 2026 Formulary (drug list and benefit rules)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug line lists 'PA' before dispensing to ensure coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    7drug tiers listed (1–7)
    Specialtyspecialty medicines must be filled at specialty pharmacy
    multipleentries include PA flags
    QL examplesquantity limits shown

    Coverage rules and formulary controls

    General coverage with restrictions

    Covered according to formulary tier with program-level edits and benefit rules; many products are conditionally covered when the listed requirements are met.

    Formulary coverage with program edits: Drug is covered according to its formulary Tier but may be subject to program edits (PA, ST, QL, AL, S, ONC) noted on the drug list.

    Member cost share determined by Tier; specialty drugs may be covered under a different benefit and must be filled at a specialty pharmacy when designated.

    Prior Authorization required when indicated: If 'PA' is listed for the drug/strength, coverage requires prior authorization before approval/claim payment.

    PA is defined on the formulary legend and absence of an approved PA may result in claim denial.

    Step therapy / therapeutic edits: If 'ST' or 'TD' is listed, specified alternative therapies or trial period must be tried/observed prior to coverage at the indicated copay/coinsurance level.

    Step therapy sequences and TD trial limits are defined on the formulary or in program guidance; providers must document prior use of required agents.

    Formulary lines, example drug entries and code tables

    Sample listed drugs with tier and requirements from formulary pagesmixed
    ANCOBON ORAL CAPSULE 250 MG, 500 MGDrug Tier = NF; Requirements / Limits = PA
    BREXAFEMME ORAL TABLET 150 MGDrug Tier = NF; Requirements / Limits = PA
    CRESEMBA ORAL CAPSULE 186 MG, 74.5 MGDrug Tier = 4; Requirements / Limits = PA
    fluconazole oral suspension for reconstitution 10 mg/ml, 40 mg/mlDrug Tier = 3
    nystatin oral suspension 100,000 unit/mlDrug Tier = 3; Requirements / Limits = QL (480 per 30 days)
    VFEND ORAL SUSPENSION FOR RECONSTITUTION 200 MG/5 ML (40 MG/ML)Drug Tier = NF; Requirements / Limits = PA
    VIVJOA ORAL CAPSULE 150 MGDrug Tier = NF; Requirements / Limits = PA; QL (18 per 84 days)
    EPCLUSA ORAL TABLET 200-50 MGDrug Tier = 6; Requirements / Limits = PA; S
    HARVONI ORAL TABLET 45-200 MGDrug Tier = 6; Requirements / Limits = PA; S
    Formulary entries (partial)mixed
    rifabutin oral capsule 150 mgDrug Tier = 3
    rifampin oral capsule 150 mg, 300 mgDrug Tier = 3
    SIRTURO ORAL TABLET 100 MG, 20 MGDrug Tier = 4; Requirements / Limits = PA
    SIVEXTRO ORAL TABLET 200 MGDrug Tier = NF; Requirements / Limits = PA
    SOLOSEC ORAL GRANULES DEL RELEASE IN PACKET 2 GRAMDrug Tier = NF; Requirements / Limits = PA
    Antibacterialsmixed
    XENLETA ORAL TABLET 600 MGDrug Tier = NF; Requirements / Limits = PA; QL (10 per 30 days)
    XIFAXAN ORAL TABLET 200 MG, 550 MGDrug Tier = 3; Requirements / Limits = PA
    Urinary tract agentsmixed
    BLUJEPA ORAL TABLET 750 MGDrug Tier = NF; Requirements / Limits = PA; QL (20 per 30 days)
    fosfomycin tromethamine oral packet 3 gramDrug Tier = 4; Requirements / Limits = QL (3 per 30 days)
    Antineoplastic & immunosuppressant drugsmixed
    AFINITOR / AFINITOR DISPERZ (everolimus formulations)Various strengths; Drug Tier = NF or 7; Requirements / Limits = PA; ONC; TD; S; QL specified for certain formulations
    abiraterone oral tablet 250 mg, 500 mgDrug Tier = 7; Requirements / Limits = PA; ONC; TD; S
    GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MGDrug Tier = 7; Requirements / Limits = PA; ONC; S; QL (1 per 1 day)

    What prescribers and pharmacies must do

    Prior Authorization

    Prior Authorization Required — high-level action summary for PA

    Prior authorization (PA) is required for many formulary products shown with a PA flag. Prescribers or pharmacies must obtain approval before dispensing to avoid claim denial. When a product line lists PA (or combined flags such as PA; S; ONC), submit a PA request with clinical justification before the fill.

    • PA = Prior Authorization required; claims without approved PA may be denied
    • Many specialty, oncology, high‑cost and intravenous products list PA; S (Specialty) and ONC (Oncology) together
    • Opioid Program (OP) and Trial Drug (TD/TD) entries may also require PA
    Documentation Required

    Prior authorization and restrictions — PA, S, QL explanation and impact

    When a formulary line includes a PA flag the provider must: obtain prior authorization before the first fill, include supporting documentation (diagnosis, prior therapies tried, dosing rationale), and adhere to any listed Quantity Limits (QL) or Step Therapy (ST) requirements. Missing PA, missing required documentation, or exceeding QL may trigger utilization management review and possible denial.

    Definitions, abbreviations and background

    Specialty medicines are typically used to treat chronic or complex conditions, have higher acquisition costs, and commonly require additional management compared with routine outpatient drugs. These agents are often handled through a specialty pharmacy channel or may be covered under a different benefit, and their formulary lines frequently include program controls such as PA (Prior Authorization), S (specialty/step routing), and QL (Quantity Limits). The HealthPartners Pharmacy and Therapeutics review process and the formulary legend define these abbreviations and the specific documentation or site‑of‑care expectations that apply.

    Specialty Medicine definition
    DefinitionSpecialty medicines: high‑cost, require more management, often filled at specialty pharmacies and may be covered under a different benefit.
    Typical usesPrescribed for chronic and complex diseases requiring specialty management
    Filling requirementPrescriptions for specialty medicines must be filled at a specialty pharmacy
    Formulary abbreviations

    Step therapy / therapeutic edit rules

    Coverage instruction
    Try specified first-line agent(s) before covering the ST‑listed medicine; if required alternatives have not been tried, prior approval from HealthPartners is needed for coverage at the lower formulary benefit.
    Examples / notes
    Select antiviral agents are annotated with 'S' and/or 'PA' (examples: LEDIPASVIR‑SOFOSBUVIR, MAVYRET, VOSEVI) indicating specialty or step‑type management may apply; explicit step sequences are not shown in this extract.
    TD flag implication
    Entries marked 'TD' indicate therapeutic/step edits may be enforced for oncology agents (examples in oncology listings include GLEEVEC, ROZLYTREK, REZLIDHIA), but specific step requirements are not detailed in this extract.
    TD‑marked items / pathway note
    TD appears alongside oncology products and generally accompanies PA, ONC, and S flags; use the oncology program requirements and therapeutic edits referenced for those products when submitting authorization requests.
    ProductFlag
    AUSTEDO (and AUSTEDO XR)
    S; PA; QL (1 per 1 day)
    DAYBUE oral solution
    S; PA; QL (120 per 1 day)
    EVRYSDI
    S; PA
    RADICAVA ORS
    S; PA
    Note
    No explicit step‑by‑step sequences are present in the extract; prior authorization (PA) is the predominant management mechanism for many products.
    Summary
    The extract does not show detailed step therapy sequences for the listed products; PA and QL controls predominate in the provided lines.
    Multi‑step sequences present?
    The provided extract lacks multi‑step sequences; entries use single 'S' or 'ST' flags without published multi‑step algorithms in this segment.

    Specified quantity limits by product

    nystatin oral suspension QL value
    Quantity limit (nystatin)480 per 30 days
    Drugnystatin oral suspension 100,000 unit/ml
    TierDrug Tier = 3 (as listed)
    VIVJOA ORAL CAPSULE 150 MG QL
    Quantity limit18 (per 84 days)
    DrugVIVJOA ORAL CAPSULE 150 MG
    RequirementPA; QL (18 per 84 days)

    Specialty channel and site-of-care guidance

    Billing Rule

    Fill specialty medicines at specialty pharmacy per formulary

    Specialty medicines must be dispensed via a specialty pharmacy and may be covered under a different benefit than retail‑dispensed medicines; check member benefits for specialty coverage rules.

    Prior Authorization

    Coordinate PA and site‑of‑care for infusion/specialty products

    Infusion or injectable specialty products flagged 'S' may require specialty channel routing or infusion‑center handling; coordinate site‑of‑care and PA accordingly.

    Note

    Verify outpatient (OP) site‑of‑care requirements

    Policy Summary
    PayerHealthPartners
    PolicyHealthPartners HSA Plus 2026 Formulary (drug list and benefit rules)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug line lists 'PA' before dispensing to ensure coverage.
    SourceLink
    On This Page
    Coverage rules and formulary controlsFormulary lines, example drug entries and code tablesWhat prescribers and pharmacies must doDefinitions, abbreviations and backgroundStep therapy / therapeutic edit rulesSpecified quantity limits by productSpecialty channel and site-of-care guidance
    Quantity limits and trial drug program: If 'QL' or 'TD' is listed, dispensing is limited to the stated quantity in the specified time period (e.g., X per Y days); trial drug (TD) initial fills may be limited (first 6 fills may be reduced supply).Examples: 1 per 1 day; 21 per 28 days; trial drug: first 6 fills may be limited

    Requests above QL will be reviewed for medical necessity and require supporting documentation.

    Specialty & oncology routing: If 'S' (specialty) or 'ONC' (oncology) is listed, the product is managed through specialty pharmacy or oncology program procedures and may require site-of-care handling.

    Specialty medicines frequently require specialty pharmacy fill and additional documentation; oncology drugs are handled under the ONC program.

    Non‑Formulary (NF) and tiering impact: Drug Tier (numeric or NF) indicates formulary placement and affects member cost share; NF entries are not covered under the formulary unless PA or alternate coverage applies.

    Refer to Summary of Plan Benefits or member account for exact cost sharing and benefit applicability.

    Per-drug utilization controls

    Per-product flags on the formulary drive utilization management and edits; providers must follow the requirement(s) listed for each specific drug/strength.

    Prior Authorization (PA): If 'PA' appears in the product Requirements / Limits, prior authorization must be obtained before the plan will approve payment for that product.

    Multiple formulary lines show 'PA' for specific strengths and formulations.

    Quantity Limits (QL): If 'QL' is listed with a numeric limit, dispensing is restricted to that amount in the specified time period unless an exception is approved.Examples: QL (1 per 1 day); QL (21 per 28 days); QL (1 per 135 days)

    Specific QL values appear next to the affected product lines.

    Specialty designation (S): If 'S' is listed, the product is managed as a specialty medicine and may require specialty pharmacy distribution and additional documentation.

    Seen on many high‑tier and oncology product lines.

    Oncology program (ONC): If 'ONC' is listed, the product is managed under the payer's oncology program and must follow oncology program routing and requirements.

    Applies to many antineoplastic agents and combinations in the table.

    Opioid / site‑of‑service flags (OP): If 'OP' or opioid program flags are listed, initial dispensing limits and program rules (e.g., limited initial supply; PA for continued therapy) apply.

    Opioid Program limits and initial supply rules are described in the formulary materials.

    Step therapy (ST) and therapeutic edits (TD): If 'ST' or 'TD' is present, the member must meet the step or trial requirements before the requested product is approved at the preferred cost share.

    Exact step sequences are specified where applicable on the formulary or in program documents.

    Formulary coverage by product

    Coverage and utilization management are determined per listed product line; each entry includes the drug name, strength, Drug Tier, and Requirements / Limits flags that govern coverage.

    Product-level conditional coverage: Each listed product entry includes drug name, strength(s), Drug Tier, and Requirements / Limits flags (PA, QL, OP, NF, ONC, S); coverage is conditional on satisfying those flags.

    Examples in the table: opioid formulations show OP and QL values; many oncology and specialty agents show PA; ONC; S.

    Opioid examples and limits: Selected opioid products list site‑of‑service (OP), PA, and explicit QL values that limit initial and ongoing dispensing (e.g., morphine ER QL 3 per 1 day; oxycodone solution QL 40 per 1 day).

    Opioid program and QL enforcement noted across multiple opioid lines.

    Antineoplastic and oncology examples: Oral and parenteral oncology agents list PA, ONC, S and often QL values (e.g., VENCLEXTA QL per day and starting pack QL per 135 days; many agents routed to oncology program).

    Refer to oncology entries for drug‑specific requirements and QL values.

    Non‑formulary (NF) entries: Products marked NF (Non‑Formulary) are noted on product lines; NF items may require PA or are excluded from standard formulary coverage unless an exception is granted.

    NF status appears alongside PA and QL on many lines.

    Examples of common Requirements / Limits shown: Examples shown on product lines include: 'PA', 'QL (numeric per time period)', 'S', 'ONC', 'OP', 'TD', 'NF'.

    See product lines for the exact combination applicable to each strength/formulation.

    Formulary controls (partial segment)

    Partial segment of outpatient formulary controls — outpatient dispensing is subject to the tier and Requirements / Limits shown for each product.

    Outpatient formulary controls: Coverage and dispensing for outpatient products are subject to the Drug Tier and any listed Requirements / Limits (PA, QL, OP).

    This segment shows tramadol and other analgesic entries with PA and QL values; outpatient flags (OP) appear for many oral formulations.

    Quantity limits enforcement: When a QL is present for an outpatient product, dispensing is limited to that quantity per the specified time period (e.g., QL (1 per 1 day), QL (80 per 1 day) for solution forms).Examples: QL (1 per 1 day); QL (80 per 1 day)

    Exceeding QL may require medical necessity documentation or will be subject to denial.

    Prior Authorization for outpatient drugs: Outpatient formulations that list 'PA' require prior authorization before coverage will be approved.

    Many outpatient product lines in this segment show PA as the primary utilization management control.

    Drugs shown as NF (Non‑Formulary) on the formulary are not covered through the standard drug list benefit unless an exception is granted. When an NF product line includes a PA (Prior Authorization) flag, coverage may be available only after an approved prior authorization or when alternative coverage pathways apply. Providers should consult the formulary line for the product-specific Requirements / Limits and submit the documentation required for a PA request if coverage is sought for an NF item.

    Formulary requirement flags and QL phrasesmixed
    QL (1 per 1 day)Quantity limit example shown for several drugs
    PAPrior Authorization required
    ONCOncology designation
    SSpecialty drug designation
    TDTherapy/diagnosis designation (as used in table)
    Drug listing (no procedure/diagnosis codes in this section)mixed
    no codes listedThis document portion lists drug product names, strengths, tiers, and utilization flags but does not include CPT/HCPCS/ICD codes in these chunks.
    nystatin oral suspension QL
    Quantity limit480 per 30 days
    BLUJEPA quantity limit
    Quantity limit20 per 30 days
    fosfomycin quantity limit
    Quantity limit3 per 30 days
    XENLETA quantity limit
    Quantity limit10 per 30 days
    Quantity Limits examples (mixed examples)
    Examples (single-day limits)1 per 1 day; 2 per 1 day
    Examples (monthly/pack limits)148 per 30 days (XROMI); 1 per 135 days (VENCLEXTA starting pack)
    Dose‑pack examplesVarious dose packs with multi-day limits (e.g., 135 days for certain starting packs)
    LYRICA ORAL SOLUTION QL (30)
    Quantity limit30 per 1 day
    DrugLYRICA ORAL SOLUTION 20 MG/ML
    RequirementPA; QL (30 per 1 day)
    Quantity limits (per day) — assorted examples
    Per‑day examples (ER/IR formulations)QL (1 per 1 day); QL (3 per 1 day)
    Benzodiazepine per‑day examplelorazepam tablet: QL (6 per 1 day)
    Migraine acute per‑day exampleQULIPTA: 1 per 1 day
    Formulary requirement flags and QL phrases (legend)mixed
    PAPrior Authorization required
    QLQuantity Limit (number per time period, e.g., X per Y days)
    SSpecialty drug designation (specialty pharmacy or channel)
    ONCOncology program designation
    TDTherapeutic/step designation
    • Provide clinical notes, prior medication history and rationale when submitting PA
    • If a product shows ST or TD, document that step requirements were met or request an exception
    • QL values (e.g., QL (4 per 30 days)) indicate enforced maximums and must be justified for overrides
    Prior Authorization

    Prior Authorization required — many listed drugs require PA

    Many listed drugs across therapeutic classes require PA — examples include specialty biologics, oncology agents, high‑cost antivirals, and select neurologic or seizure medications. Specialty (S) designation often accompanies PA and implies additional paperwork and routing to specialty/pharmacy channels.

    • Oncology products frequently display PA; ONC; S; QL (e.g., multiple oral antineoplastics)
    • Neurology/epilepsy agents (KEPPRA, VIMPAT, XCOPRI) often show PA and QL
    • Hepatitis C/hepatitis antivirals and other high‑cost antivirals commonly show PA; S
    Prior Authorization

    Prior authorization required when PA flag present — PA with ONC/S/TD context

    When a specialty, IV or clotting‑factor product lists PA (often with S), the provider must submit specialty‑level documentation (treatment plan, dosing schedule, prior authorizations for past courses) and coordinate with the plan’s specialty pharmacy if required.

    • Injectable clotting‑factor and IV biologics are frequently PA; S — e.g., ALPHANATE, ALPROLIX, JIVI
    • Specialty products may require quantities expressed per dosing period (units per 28/30 days) and reconciliation documentation
    Prior Authorization

    Prior Authorization required — examples of products requiring PA (neurology/epilepsy listing)

    PA is enforced for many named products in the table. Examples: certain opioid and analgesic controlled‑release products, selected antiepileptics, migraine biologics, and numerous specialty oncology agents. Check the formulary line for the PA flag and any co‑flags (ST, QL, OP, ONC) before prescribing or dispensing.

    • Opioid product examples: OXYCONTIN, OXYMORPHONE entries list PA; OP; QL
    • Antiepileptic examples: KEPPRA, VIMPAT, XCOPRI show PA (often with QL)
    • Migraine biologics: AIMOVIG, AJOVY include PA; QL
    Documentation Required

    PA plus quantity limits — examples where both PA and QL apply

    PA may be combined with Quantity Limits (QL); when both apply, supporting documentation is required to exceed the stated QL. Requests above QL will be reviewed for medical necessity and may be denied without sufficient justification.

    • QL examples: LYRICA CR and immediate‑release LYRICA list PA; QL (per day) limits
    • Claims exceeding QL require documentation of medical necessity and prior use within limit
    • Tramadol and other opioid entries frequently show PA; OP; QL — adhere to opioid program limits
    Prior Authorization

    Prior Authorization required for specified products — specialty/high‑cost examples

    Specialty and oncology flags (S, ONC, TD) signal that additional supporting documentation and prior authorization steps are required; these products are routed through specialty review and may have per‑course or per‑period QL (for example, QL expressed as units per 28 or 30 days).

    • ONC and TD typically accompany PA for oral antineoplastics and targeted therapies
    • Examples show QL expressed as a count per day or per 28/30 days (e.g., QL (21 per 28 days))
    • Specialty routing may change where the drug is dispensed (specialty pharmacy required)
    Prior Authorization

    Specialty IV products require PA — injectable clotting‑factor/IV examples

    Some high‑cost IV and specialty products (including clotting factors and enzyme/replacement therapies) explicitly require PA and specialty handling. Expect prior authorization review to include dosing logs, prior authorization history, and documentation of diagnosis and therapeutic necessity.

    • IV clotting‑factor products (e.g., ALPHANATE, ALPROLIX, ALTUVIIIO) list PA; S
    • Remodulin and other parenteral specialty agents show PA; S routing
    • Submit weight/dosing and units per period documentation for IV products when requested
    Prior Authorization

    Rivaroxaban PA/QL — anticoagulant examples with PA and QL

    Rivaroxaban entries show mixed requirements: certain formulations list PA with a QL and others list QL only. Verify the specific NDC/formulation; if PA; QL is present, obtain PA and ensure quantity does not exceed the stated limit.

    • Rivaroxaban oral suspension: Requirements = PA; QL (20 per 1 day)
    • Rivaroxaban 2.5 mg tablets: Requirements = QL (2 per 1 day)
    Denial Risk

    Opioid Program denial risk — specific opioid program enforcement if PA not obtained

    For opioid‑program flagged products (OP), initial prescriptions may be limited to smaller supply and longer therapy often requires PA. Failure to obtain required authorization for OP entries or to adhere to QL limits increases the risk of coverage denial.

    • Opioid program entries (OP) denote shorter initial supply and enforced QL
    • Longer opioid therapy requires prior authorization — obtain PA early to avoid interruption
    • Claims for opioid products without required PA or exceeding QL are at higher risk for denial
    Denial Risk

    UM triggers for denial — missing PA/S/ONC may cause denial

    Utilization management (UM) triggers for denial include: absence of required PA, missing or insufficient supporting documentation, failure to meet ST/TD requirements, and exceeding QL without medical‑necessity justification. Providers should confirm requirements on the formulary line before prescribing.

    • PA missing on a PA‑designated product may result in denial of coverage
    • ST/TD requirements must be documented or an exception requested
    • Exceeding a QL without justification can trigger UM denial
    Documentation Required

    Quantity limit enforcement — QL exceedance handling and documentation

    Quantity limits are enforced where listed (QL). Requests above the QL will be clinically reviewed; to avoid denial, include documentation showing prior use at the requested dose, clinical necessity, and rationale for exceeding the limit.

    • Examples: QL (4 per 30 days), QL (21 per 28 days), QL (1 per 1 day) — adhere to the per‑period unit definitions
    • Pharmacies submitting overrides should attach medical justification and prior therapy records
    • Some QL values apply per day, per 28 days or per 30 days — confirm the period before submitting
    Step Therapy

    Step Therapy Requirement — explanation of ST flag and its effect

    Step therapy (ST) applies where shown; the prescriber must document that required first‑line therapies were tried and failed or request an exception. For certain biologics and specialty agents, ST is required and is shown alongside QL where applicable.

    • ST = Step Therapy; REPATHA examples show ST with QL limits
    • If ST is indicated (ST or ST; QL), document prior agents tried and outcome
    • When a product lists ST but no specifics are on the line, consult the plan or prior authorization criteria for the step‑therapy algorithm
    Documentation Required

    Documentation for quantities over limit — supporting docs required for exceptions

    Documentation must accompany PA and any request to exceed QL or bypass ST. For specialty/oncology products include treatment plan, prior regimen history, dosing schedule, and any relevant lab or imaging reports. Insufficient documentation increases the chance of denial.

    • Supporting docs: diagnosis, prior therapies, response/failure notes, dosing and duration
    • Specialty/ONC products: include oncology treatment plan and cycle counts (units per 28/30 days)
    • Quantities over a limit require explicit supporting clinical rationale
    Note

    Required documentation flags — mapping of PA/ST/S/QL to provider actions

    The formulary legend and table headers explain symbols and where to find specific PA/ST/QL meanings. Always consult the table heading and the explanation section (List of Abbreviations) for symbol definitions before acting on a formulary line.

    • Refer to the List of Abbreviations for PA, ST, QL, S, ONC, OP, TD
    • Table entries include both the drug line and a Requirements / Limits field — review both
    • When in doubt, contact HealthPartners prior authorization services or check myHealthPartners for plan‑specific rules
    PAPrior Authorization Required
    STStep Therapy Required
    ALAge Limit
    QLQuantity Limit
    SCSmoking Cessation Benefit
    Prior Authorization short label
    PA (short)Prior Authorization Required
    ActionPA indicates pre‑approval is required before benefit payment
    Where shownPA appears in Requirements / Limits column next to many drugs
    Quantity Limit short label (QL x per y days)
    QL formatQL (X per Y days) — e.g., QL (1 per 1 day)
    MeaningIndicates maximum allowed quantity over the specified time period
    EnforcementExceeding QL may trigger claim denial or require documentation/PA
    Formulary tier designations and NF — mapping note
    Tier mappingTier 1–7 determine member cost share; 'NF' indicates Non‑Formulary
    Tier examplesTier 1 = Preventive Generics; Tier 6 = Specialty Brands; Tier 7 = Oral Chemotherapy
    ImpactTier affects copay/coinsurance and prior authorization pathways
    Specialty flag (S) definition
    S flagSpecialty designation — indicates specialty pharmacy handling or special routing
    ImplicationMay require PA and specialty channel for dispensing
    Seen withMany injectable/infusible and high‑cost agents (PA; S) in the table
    Prior Authorization (short) duplicate
    PA (repeat)Prior Authorization — pre‑approval required
    UsageListed as 'PA' in Requirements / Limits column for many products
    Denial riskClaims may be denied if PA not obtained
    Quantity Limit (short) duplicate
    QL (repeat)Quantity Limit — specified as 'X per Y days' next to product
    InterpretationSpecifies maximum dispense amount over time unless exception documented
    ExamplesSee per‑product QL values (e.g., 1 per 1 day; 21 per 28 days)
    Program or special flags (ONC, S, TD, AL) mapping
    ONCOncology program designation — managed under payer's oncology program
    SSpecialty designation — specialty pharmacy/channel handling
    TDTherapeutic/step edit indicator
    QL detailed example (21 per 28 days) definition
    Example QL detail'21 per 28 days' indicates maximum 21 units in a 28‑day period
    UseApplied to multiple oncology and specialty oral agents (e.g., IBRANCE, lenalidomide)
    DocumentationExceptions require supporting documentation/PA
    PA short mapping
    PA shortPrior Authorization (PA) — pre‑approval required
    Where usedShown in Requirements / Limits column to indicate PA requirement
    ConsequenceLack of PA may result in denial
    ONC / S / TD codes explained
    ONC/S/TD explanationONC = oncology program; S = specialty; TD = therapeutic/step edit
    ApplicationFlags indicate program routing and additional management requirements
    DocumentationProvider must supply required documentation when these flags appear
    Table abbreviations mapping — 'see table legend' note
    Legend noteTable abbreviations and symbols are defined at the beginning of the formulary table (see table legend)
    Common abbreviationsPA, QL, ONC, S, TD, OP, NF
    Provider actionConsult legend to interpret Requirements / Limits flags
    formulary abbreviations duplicate mapping
    PA mapping duplicatePA = Prior Authorization Required
    ST mapping duplicateST = Step Therapy Required
    QL mapping duplicateQL = Quantity Limit
    PA mapping duplicate
    PA mapping duplicatePA indicates pre‑approval required before coverage
    Denial riskClaims may be denied if PA not obtained
    DocumentationPA requests require supporting clinical documentation
    QL mapping duplicate
    QL mapping duplicateQL = Quantity Limit (X per Y days)
    EnforcementExceeding QL can trigger denial or require PA/documentation
    ExamplesPer‑day and per‑30/28/90 day examples listed in table
    S flag mapping duplicate
    S flag duplicateS = Specialty designation; indicates specialty pharmacy or special routing
    ImplicationOften paired with PA and QL for specialty products
    Site of careMay require specialty channel or infusion center handling
    NF mapping duplicate
    NF mappingNF = Non‑Formulary — not covered under formulary unless PA/alternate coverage applies
    EffectMay require PA for exception coverage
    Provider adviceCheck formulary legend and PA pathways for NF agents
    PA mapping duplicate
    PA mapping duplicate 2PA indicates prior authorization required
    UseAppears across many product lines in Requirements / Limits column
    ConsequenceClaims may be denied without PA
    QL mapping duplicate
    QL mapping duplicate 2QL = Quantity Limit — maximum units over specified time
    Examples1 per 1 day; 4 per 30 days; 21 per 28 days
    ExceptionsRequests above QL require review and documentation
    S mapping duplicate
    S mapping duplicate 2S = Specialty (step/special routing)
    Typical productsInjectable/infusible high‑cost agents and many biologics
    DocumentationSpecialty designation often requires specialty pharmacy and PA
    Table abbreviations / symbols mapping
    Table symbolsAbbreviations such as PA, QL, S, ONC, TD are defined in the table legend
    Provider noteConsult the table legend at the start of the formulary for definitions
    Where notedLegend referenced repeatedly throughout document chunks
    PA short mapping duplicate
    PA short mapping duplicatePA = Prior Authorization
    ActionRequires pre‑approval before coverage/payment
    Found inRequirements / Limits column for many drugs
    QL per-day mapping
    Per‑day QL shorthandQL (X per 1 day) indicates maximum daily units (e.g., QL (1 per 1 day))
    UsageApplied to many immediate‑release or short‑course formulations
    EnforcementExceeding daily QL may require PA or be denied
    OP/site designation mapping
    OPOP = Outpatient site indicator (used for some formulations)
    ImplicationDenotes outpatient dispensing/setting for listed products
    CheckSee table legend for site‑of‑care interpretation
    formulary abbreviations duplicate
    Formulary abbreviations duplicatePA, ST, AL, QL, SC defined in legend
    UseAbbreviations guide interpretation of Requirements / Limits
    ReferenceSee table legend at beginning of formulary
    PA mapping duplicate
    PA mapping duplicate 3PA indicates prior authorization requirement
    ConsequencesClaims may be denied if PA missing
    DocumentationProviders must submit required PA documentation
    S mapping duplicate
    S mapping duplicate 3S = Specialty designation requiring specialty handling
    Common pairingOften paired with PA and QL for specialty agents
    BenefitMay be covered under a different benefit and require specialty pharmacy
    QL mapping duplicate
    QL mapping duplicate 3QL = Quantity Limit (X per Y days)
    Provider actionRequests above QL require documentation for medical necessity
    ExamplesPer‑day and per‑30/28/90 day limits appear throughout the table
    Drug Tier mapping note
    Drug Tier mapping noteTiers 1–7 determine member cost share; Tier 7 used for oral chemotherapy; NF indicates non‑formulary
    ActionCheck member plan benefits for exact copay/coinsurance by tier
    Where usedTier shown on each product line in the table
    Products subject to ST
    TRINTELLIX (listed with ST; QL 1 per 1 day)
    Zolpidem extended‑release (listed ST; QL 1 per 1 day)
    Observation
    Multiple formulary lines include an 'S' flag indicating step or specialty handling across high‑cost and specialty products, but the extract does not provide accompanying step sequences.
    Specialty / high‑cost examples
    Remodulin (injection) — flagged 'PA; S' (specialty); specific sequencing not specified in extract.
    Praluent / other PCSK9 agents — some variants flagged 'PA; S' or 'ST'; sequencing details not shown.
    REPATHA variantStep therapy status
    REPATHA Pushtronex wearable injector 420 mg/3.5 mL
    ST; QL (3.5 per 28 days)
    REPATHA SureClick pen 140 mg/ML
    ST; QL (2 per 28 days)
    REPATHA syringe 140 mg/ML
    ST; QL (2 per 28 days)
    LAGEVRIO (EUA) ORAL CAPSULE 200 MG QL
    Quantity limitQL (8 per 1 day)
    DrugLAGEVRIO (EUA) ORAL CAPSULE 200 MG
    ContextDaily capsule limit as listed in Requirements / Limits
    PAXLOVID ORAL TABLETS, DOSE PACK QL
    Quantity limitQL (4 per 1 day) or QL (6 per 1 day) depending on pack
    DrugPAXLOVID ORAL TABLETS, DOSE PACK
    NoteLimit varies by dose pack formulation
    ALINIA ORAL SUSPENSION / tablet QL values
    Oral suspension QLQL (180 per 30 days)
    Tablet QLALINIA tablet QL (6 per 30 days)
    DrugALINIA (oral suspension / tablet)
    linezolid oral tablet 600 mg QL
    Quantity limitQL (2 per 1 day)
    Druglinezolid oral tablet 600 mg
    ContextDaily tablet dispensing limit
    TEMBEXA ORAL SUSPENSION / TABLET QL
    Suspension QLQL (65 per 8 days)
    Tablet QLQL (4 per 8 days)
    DrugTEMBEXA (oral suspension / tablet)
    STROMECTOL ORAL TABLET QL
    Quantity limit40 per 30 days
    DrugSTROMECTOL ORAL TABLET 3 MG
    ContextMonthly QL as listed
    tobramycin inhalation solutions QL examples
    Quantity examplesTobramycin inhalation solutions QL: 4–5 per 1 day depending on formulation
    DrugTOBI and related inhalation solutions
    FlagsPA; S; QL present for inhaled antibiotic formulations
    XENLETA ORAL TABLET QL
    Quantity limit10 per 30 days
    DrugXENLETA ORAL TABLET 600 MG
    RequirementPA; QL (10 per 30 days)
    BLUJEPA ORAL TABLET QL
    Quantity limit20 per 30 days
    DrugBLUJEPA ORAL TABLET 750 MG
    RequirementPA; QL (20 per 30 days)
    fosfomycin packet QL
    Quantity limit3 per 30 days
    Drugfosfomycin tromethamine oral packet 3 gram
    NoteQL (3 per 30 days) as listed in Requirements / Limits
    IBRANCE QL example (21 per 28 days)
    Quantity limit21 per 28 days
    DrugIBRANCE (and other oral oncology agents) — QL shown as 21 per 28 days
    ContextApplied to certain oncology oral agents (PA; ONC; S)
    lenalidomide QL example (21)
    Quantity limit21 per 28 days
    Druglenalidomide — QL (21) shown for listed strengths
    RequirementPA; ONC; S; QL present
    XROMI ORAL SOLUTION QL (148)
    Quantity limit148 per 30 days
    DrugXROMI ORAL SOLUTION
    ContextLarge monthly QL as listed in table
    VENCLEXTA STARTING PACK QL
    Quantity limit1 per 135 days (starting pack)
    DrugVENCLEXTA STARTING PACK
    ContextStarting pack QL specified as 1 per 135 days
    DIACOMIT ORAL CAPSULE QL (12)
    Quantity limit12 per 1 day
    DrugDIACOMIT ORAL CAPSULE 250 MG (dose/powder examples)
    FlagsPA; S; QL present
    VIMPAT ORAL SOLUTION QL (40)
    Quantity limit40 per 1 day
    DrugVIMPAT ORAL SOLUTION 10 MG/ML
    RequirementPA; QL (40 per 1 day)
    LYRICA CR ORAL TABLET QL (1-2)
    Quantity limit1–2 per 1 day (depending on strength)
    DrugLYRICA CR ORAL TABLET 165 MG / 330 MG
    RequirementPA; QL specified per strength
    VALTOCO NASAL SPRAY QL (5)
    Quantity limit5 per 30 days
    DrugVALTOCO NASAL SPRAY
    RequirementQL (5 per 30 days)
    GRALISE ER QL (1)
    Quantity limit1 per 1 day
    DrugGRALISE ORAL TABLET ER 300–750 mg
    RequirementPA; QL present
    AIMOVIG QL (1)
    Quantity limit1 per 28 days
    DrugAIMOVIG autoinjector
    RequirementPA; QL (1 per 28 days)
    AJOVY (auto-injector) QL (1.5)
    Quantity limit1.5 per 28 days
    DrugAJOVY (auto‑injector)
    RequirementPA; QL (1.5 per 28 days)
    AJOVY (syringe) QL (4.5)
    Quantity limit4.5 per 84 days
    DrugAJOVY (syringe)
    RequirementPA; QL (4.5 per 84 days)
    ELYXYB QL (144)
    Quantity limit144 per 30 days
    DrugELYXYB ORAL SOLUTION
    RequirementPA; QL (144 per 30 days)
    EMGALITY (pen/syringe 120 mg) QL (1)
    Quantity limit1 per 28 days
    DrugEMGALITY pen/syringe 120 mg
    RequirementPA; QL (1 per 28 days)
    EMGALITY (syringe 300 mg) QL (3)
    Quantity limit3 per 28 days
    DrugEMGALITY syringe 300 mg
    RequirementPA; QL (3 per 28 days)
    ERGOMAR QL (60)
    Quantity limit60 per 90 days
    DrugERGOMAR sublingual tablet
    RequirementPA; QL (60 per 90 days)
    ergotamine-caffeine QL (120)
    Quantity limit120 per 90 days
    Drugergotamine‑caffeine oral tablet
    RequirementPA; QL (120 per 90 days)
    FROVA QL (3)
    Quantity limit3 per 7 days
    DrugFROVA (frovatriptan)
    RequirementPA; QL (3 per 7 days)
    NURTEC ODT QL (8)
    Quantity limit8 per 30 days
    DrugNURTEC ODT
    RequirementPA; QL (8 per 30 days)
    QULIPTA QL (1)
    Quantity limit1 per 1 day
    DrugQULIPTA oral tablet
    RequirementPA; QL (1 per 1 day)
    sumatriptan succinate subcutaneous cartridge/pen QL (5)
    Quantity limit5 per 30 days
    Drugsumatriptan succinate subcutaneous cartridge/pen
    RequirementQL (5 per 30 days)
    SYMBRAVO QL (12)
    Quantity limit12 per 28 days
    DrugSYMBRAVO
    RequirementPA; QL (12 per 28 days)
    TREXIMET QL (18)
    Quantity limit18 per 28 days
    DrugTREXIMET
    RequirementPA; QL (18 per 28 days)
    WAINUA QL (0.8)
    Quantity limit0.8 per 30 days
    DrugWAINUA (injector)
    RequirementPA; S; QL (0.8 per 30 days)
    AMPYRA QL (2)
    Quantity limit2 per 1 day
    DrugAMPYRA (dalfampridine)
    RequirementPA; S; QL (2 per 1 day)
    WAINUA SUBCUTANEOUS AUTO-INJECTOR QL (0.8)
    Quantity limit0.8 per 30 days
    DrugWAINUA subcutaneous auto‑injector 45 mg/0.8 mL
    RequirementPA; S; QL (0.8 per 30 days)
    ZEPOSIA ORAL CAPSULE QL (1)
    Quantity limit1 per 1 day
    DrugZEPOSIA oral capsule 0.92 mg
    RequirementPA; S; QL (1 per 1 day)
    ZEPOSIA STARTER KIT QL (28)
    Quantity limit28 per 180 days
    DrugZEPOSIA starter kit (28‑day)
    RequirementPA; S; QL (28 per 180 days)
    carisoprodol oral tablet QL (4)
    Quantity limit4 per 1 day
    Drugcarisoprodol oral tablet 250 mg
    RequirementPA; QL (4 per 1 day)
    meprobamate tablet QL (6)
    Quantity limit6 per 1 day
    Drugmeprobamate oral tablet 200 mg, 400 mg
    RequirementPA; QL (6 per 1 day)
    PYRIDOSTIGMINE BROMIDE QL (1)
    Quantity limit1 per 1 day
    DrugPYRIDOSTIGMINE BROMIDE oral tablet 30 mg
    RequirementPA; QL (1 per 1 day)
    morphine ER QL (3)
    Quantity limit3 per 1 day
    Drugmorphine oral tablet extended release
    RequirementPA; QL (3 per 1 day)
    morphine rectal suppository QL (8)
    Quantity limit8 per 1 day
    Drugmorphine rectal suppository
    RequirementOP; QL (8 per 1 day)
    oxycodone-acetaminophen solution QL (20)
    Quantity limit20 per 1 day
    Drugoxycodone‑acetaminophen oral solution 10‑300 mg/5 ml
    RequirementPA; OP; QL (20 per 1 day)
    prolate oral solution QL (20)
    Quantity limit20 per 1 day
    Drugprolate oral solution 10‑300 mg/5 ml
    RequirementPA; OP; QL (20 per 1 day)
    ketorolac injection QL (20)
    Quantity limit20 per 30 days
    Drugketorolac injection (various IM/IV) — QL examples
    RequirementQL (20 per 30 days)
    tramadol oral solution QL (80)
    Quantity limit80 per 1 day
    Drugtramadol oral solution 5 mg/ml
    RequirementPA; OP; QL (80 per 1 day)
    TRAMADOL ER 300 MG QL (1 per 1 day)
    Quantity limit1 per 1 day
    DrugTRAMADOL ER 300 mg — QL (1 per 1 day)
    RequirementPA; QL as listed
    TRAMADOL ER 100 MG QL (3 per 1 day)
    Quantity limit3 per 1 day
    DrugTRAMADOL ER 100 mg — QL (3 per 1 day)
    RequirementPA; QL as listed
    TRAMADOL ORAL SOLUTION QL (80 per 1 day)
    Quantity limit80 per 1 day
    DrugTRAMADOL oral solution 5 mg/ml — QL (80 per 1 day)
    RequirementPA; OP; QL specified
    ZUBSOLV QL (varies by strength)
    Quantity limitVaries by strength: QL (1–12 per 1 day)
    DrugZUBSOLV sublingual tablet (various strengths)
    NoteQL depends on listed strength as shown in formulary lines
    alprazolam QL (varies)
    Quantity limitQL (2–6 per 1 day depending on formulation)
    Drugalprazolam (various forms)
    ContextDaily QL varies by formulation as listed
    FANAPT QL/PA (PA present)
    RequirementPA required (QL not specified in this segment)
    DrugFANAPT (various strengths)
    NotePA flag present for multiple formulations
    lorazepam tablet QL (6 per 1 day)
    Quantity limitQL (6 per 1 day)
    Druglorazepam oral tablet 0.5/1 mg
    ContextDaily dispensing limit as listed
    methylphenidate solution QL (30 per 1 day)
    Quantity limitQL (30 per 1 day)
    Drugmethylphenidate HCl oral solution 10 mg/5 ml
    ContextDaily QL as listed in requirements
    methylphenidate solution QL (60 per 1 day)
    Quantity limitQL (60 per 1 day)
    Drugmethylphenidate HCl oral solution 5 mg/5 ml
    ContextHigher daily QL for lower‑strength solution
    QUILLIVANT XR QL (12)
    Quantity limit12 (per 1 day) — as listed
    DrugQUILLIVANT XR oral suspension — QL (12)
    RequirementPA; QL present
    SODIUM OXYBATE / XYREM / XYWAV QL (18)
    Quantity limit18 per 1 day
    DrugSodium Oxybate (XYREM/XYWAV)
    RequirementPA; S; QL (18 per 1 day)
    AVONEX QL (1)
    Quantity limit1 per 28 days
    DrugAVONEX injection
    RequirementPA; QL (1 per 28 days)
    REBIF QL (6 / 4.2)
    Quantity limit6 per 30 days
    DrugREBIF (syringe/pen) — QL (6 per 30 days) or 4.2 per 28 days depending on formulation
    RequirementPA; S; QL present
    MAYZENT STARTER dose pack QL (12 per 5 days)
    Quantity limit12 per 5 days (starter dose pack)
    DrugMAYZENT STARTER dose pack (0.25 mg, 12 tabs)
    RequirementPA; S; QL (12 per 5 days)
    PLEGRIDY QL (1 per 28 days)
    Quantity limit1 per 28 days
    DrugPLEGRIDY formulations
    RequirementPA; S; QL (1 per 28 days)
    PONVORY starter pack QL (1 per 1 day)
    Quantity limit1 per 1 day
    DrugPONVORY starter pack / tablet
    RequirementPA; S; QL (1 per 1 day)
    TECFIDERA QL (2 per 1 day)
    Quantity limit2 per 1 day
    DrugTECFIDERA oral capsule 120/240 mg
    RequirementPA; QL (2 per 1 day)
    REBIF syringe/pen QL (6 / 4.2)
    Quantity limit6 per 30 days or 4.2 per 28 days depending on formulation
    DrugREBIF (with albumin) syringe/pen
    RequirementPA; S; QL as listed
    VUMERITY QL (4 per 1 day)
    Quantity limit4 per 1 day
    DrugVUMERITY oral capsule 231 mg
    RequirementPA; S; QL (4 per 1 day)
    KERENDIA QL (1 per 1 day)
    Quantity limit1 per 1 day
    DrugKERENDIA oral tablet
    RequirementPA; QL (1 per 1 day)
    ARIXTRA syringe QL (24)
    Quantity limit24 per 30 days
    DrugARIXTRA subcutaneous syringe 10 mg/0.8 ml
    RequirementPA; QL (24 per 30 days)
    ARIXTRA syringe QL (15)
    Quantity limit15 per 30 days
    DrugARIXTRA subcutaneous syringe 2.5 mg/0.5 ml
    RequirementPA; QL (15 per 30 days)
    ARIXTRA syringe QL (12)
    Quantity limit12 per 30 days
    DrugARIXTRA subcutaneous syringe 5 mg/0.4 ml
    RequirementPA; QL (12 per 30 days)
    ELIQUIS dose pack/tablet QL (74)
    Quantity limit74 (per 30 days)
    DrugELIQUIS dose packs/tablets (various) — QL (74)
    ContextAs noted in formulary dose‑pack/tablet entries
    enoxaparin syringe QL examples
    Quantity limitVaries by strength (examples shown: 6 per 1 day; 48 per 30 days; 36 per 30 days)
    Drugenoxaparin subcutaneous syringes/solutions
    NoteQL depends on syringe strength/format as listed
    HYMPAVZI PEN QL (4)
    Quantity limit4 per 28 days
    DrugHYMPAVZI PEN
    RequirementPA; S; QL (4 per 28 days)
    HYMPAVZI PEN duplicate QL (4)
    Quantity limit duplicate4 per 28 days
    DrugHYMPAVZI PEN (duplicate listing)
    NotePA; S; QL (4 per 28 days)
    LOVENOX SUBCUTANEOUS SOLUTION QL (6)
    Quantity limit6 per 1 day
    DrugLOVENOX subcutaneous solution 300 mg/3 ml
    RequirementQL (6 per 1 day)
    LOVENOX syringe QL (2)
    Quantity limit2 per 1 day
    DrugLOVENOX subcutaneous syringe 100 mg/ml, 150 mg/ml
    RequirementQL (2 per 1 day)
    rivaroxaban suspension QL (20)
    Quantity limit20 per 1 day
    Drugrivaroxaban oral suspension for reconstitution 1 mg/ml
    RequirementPA; QL (20 per 1 day)
    XARELTO DVT-PE TREAT 30D START dose pack QL (51)
    Quantity limit51 (30‑day start pack)
    DrugXARELTO DVT‑PE TREAT 30D START dose pack
    RequirementQL (51 for 30‑day start pack)
    PRALUENT PEN QL (2)
    Quantity limit2 per 28 days
    DrugPRALUENT PEN
    RequirementPA; QL (2 per 28 days)

    OP/OP flags indicate outpatient dispensing or site‑of‑service; when OP is shown, verify benefit and site‑of‑care requirements before arranging treatment.

    Note

    Confirm OP/site indicators for oral formulations

    Some oral formulations include OP/site indicators — providers should confirm appropriate dispensing setting and any PA/site requirements shown on the line.

    Prior Authorization

    Arrange PA and infusion‑center coordination for injectable specialty drugs

    Injectable specialty products listed with PA and S (e.g., REMODULIN, FLOLAN) may require infusion‑center coordination and prior authorization; providers must secure PA and arrange specialty distribution.

    Billing Rule

    Route 'S'‑flagged products through specialty distribution

    An 'S' flag on a formulary line indicates specialty channel or specialty distribution is required; providers must route dispensing to specialty pharmacy when 'S' is present.